IRSN-23 gene diagnosis enhances breast cancer subtype classification and predicts response to neoadjuvant chemotherapy: new validation analyses
This study offers new validation analyses of IRSN-23 in predicting chemotherapy efficacy, showing high reproducibility. The findings indicate the clinical value of using IRSN-23 for refining breast cancer subtype classification, with implications for personalized treatment strategies and improved patient outcomes.
Authors
- Yasuto Naoi (ORCID: https://orcid.org/0000-0002-6090-0137)
- Tomonori Tanei (ORCID: https://orcid.org/0000-0003-2183-8681)
- Masafumi Shimoda (ORCID: https://orcid.org/0000-0002-0832-9877)
- Hideo Matsuda (ORCID: https://orcid.org/0000-0002-4701-3779)
- Keiichiro Honma (ORCID: https://orcid.org/0000-0001-5193-5891)
- Yoshiaki Sota (ORCID: https://orcid.org/0000-0001-5963-652X)
- Shigeto Seno (ORCID: https://orcid.org/0000-0003-3861-6444)
- Kenzo Shimazu (ORCID: https://orcid.org/0000-0002-0837-2357)
Institutions
- Kyoto Prefectural University of Medicine (JP)
- Osaka International Cancer Institute (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Breast Cancer
- Published
- 2025-03-24
- DOI
- https://doi.org/10.1007/s12282-025-01687-6
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Osaka University
- Japan Society for the Promotion of Science